Stockreport

Aerovate Therapeutics Announces Full-Year 2023 Financial Results and Business Highlights

Aerovate Therapeutics, Inc.  (AVTE) 
PDF Topline data expected in June 2024 from Phase 2b portion of the IMPAHCT global Phase 2b/Phase 3 clinical trial of AV-101 for pulmonary arterial hypertension (PAH) Compl [Read more]